Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

Allogene Therapeutics, Inc. ALLO

· Materials · Biological Products, (No Diagnostic Substances)

FY2025 10-K, filed 2026-03-12
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 4/5 core metrics

Latest reported annual revenue changed -100.0% from the prior reported annual observation.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Revenue contracted

    Latest reported annual revenue changed -100.0% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

  • Operating margin compressed

    Operating margin changed -896827.3 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2024-12-31.

  • Free cash flow was negative

    Latest reported free cash flow was -$150M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • 3 filing risk checks flagged

    Flagged areas: Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Latest annual revenue growth
-100.0%
as of 2025-12-31
Latest annual operating margin
-1241813.6%
as of 2024-12-31
Free cash flow
-$150M
as of 2025-12-31
ROIC snapshot
-37.9%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

3of 6 rule-based checks flagged
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-12prior period 2024-12-31 from the same filingView filing
By business segment
Revenue
  • Reportable Segment$0
    share n/a
    -100.0% yoy

No consolidated figure stored for this period; shares are of the filed sum.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,104 US-listed filers · 791 in Materials
MetricValuevs all filersvs sector
Return on equity
net income ÷ stockholders' equity (positive equity only)
-65.3%
16thof 3,577
bottom third
35thof 701
middle third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-8.6%
72ndof 3,291
top third
65thof 588
middle third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
-36.1%
89thof 2,805
top third
77thof 517
top third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-8.6%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-36.1%
change in net operating assets ÷ average net operating assets
Cash-backed years
3 of 3
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
-
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 44 changed periods, 30 largest shown
Line itemPeriodFirst reportedLatest filingChangeFilings
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
fiscal year 2021-12-31$38.5M
10-K 2022-02-23
$114M
10-K 2024-03-14
+196.4%first · latest · 4 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2022-12-31$885K
10-K 2023-02-28
$95K
10-K 2024-03-14
-89.3%first · latest · 6 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2022-09-30$889K
10-Q 2022-11-02
$99K
10-K 2024-03-14
-88.9%first · latest
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2022-06-30$836K
10-Q 2022-08-09
$104K
10-K 2024-03-14
-87.6%first · latest
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2023-03-31$273K
10-Q 2023-05-03
$86K
10-K 2024-03-14
-68.5%first · latest
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2022-03-31$406K
10-Q 2022-05-04
$147K
10-K 2024-03-14
-63.8%first · latest
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2023-09-30$236K
10-Q 2023-11-02
$86K
10-K 2024-03-14
-63.6%first · latest
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2021-12-31$423K
10-K 2022-02-23
$156K
10-K/A 2024-03-14
-63.1%first · latest · 6 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2023-06-30$229K
10-Q 2023-08-02
$86K
10-K 2024-03-14
-62.5%first · latest
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2023-06-30$44K
10-Q 2023-08-02
$22K
10-Q 2024-08-07
-50.0%first · latest · 3 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2023-09-30$43K
10-Q 2023-11-02
$22K
10-Q 2024-11-07
-48.8%first · latest · 3 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2022-09-30$49K
10-Q 2022-11-02
$27K
10-K 2024-03-14
-44.9%first · latest · 3 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2023-03-31$52K
10-Q 2023-05-03
$30K
10-Q 2024-05-13
-42.3%first · latest · 3 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2022-03-31$61K
10-Q 2022-05-04
$39K
10-K 2024-03-14
-36.1%first · latest · 3 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
fiscal year 2022-12-31$243K
10-K 2023-02-28
$156K
10-K 2024-03-14
-35.8%first · latest · 3 filings carry it
Operating income
OperatingIncomeLoss
fiscal year 2021-12-31-$256M
10-K 2022-02-23
-$180M
10-K 2024-03-14
+29.6%first · latest · 4 filings carry it
Net income
NetIncomeLoss
fiscal year 2021-12-31-$257M
10-K 2022-02-23
-$182M
10-K 2024-03-14
+29.2%first · latest · 4 filings carry it
Net income
NetIncomeLoss
fiscal year 2020-12-31-$250M
10-K 2021-02-25
-$316M
10-K/A 2024-03-14
-26.4%first · latest · 4 filings carry it
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
quarter 2022-06-30$86K
10-Q 2022-08-09
$64K
10-K 2024-03-14
-25.6%first · latest · 3 filings carry it
Net income
NetIncomeLoss
quarter 2022-06-30-$74.8M
10-Q 2022-08-09
-$80.3M
10-K 2024-03-14
-7.4%first · latest · 5 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2020-12-31$1.08B
10-K 2021-02-25
$1.01B
10-K 2024-03-14
-6.1%first · latest · 11 filings carry it
Equity issued
ProceedsFromIssuanceOfCommonStock
fiscal year 2020-12-31$622M
10-K 2021-02-25
$596M
10-K/A 2024-03-14
-4.2%first · latest · 4 filings carry it
Total liabilities
Liabilities
balance at 2022-03-31$109M
10-Q 2022-05-04
$113M
10-K 2024-03-14
+3.1%first · latest
Total liabilities
Liabilities
balance at 2021-12-31$122M
10-K 2022-02-23
$126M
10-K/A 2024-03-14
+2.8%first · latest · 6 filings carry it
Total liabilities
Liabilities
balance at 2023-09-30$129M
10-Q 2023-11-02
$133M
10-K 2024-03-14
+2.8%first · latest
Total liabilities
Liabilities
balance at 2023-06-30$148M
10-Q 2023-08-02
$152M
10-K 2024-03-14
+2.4%first · latest
Total liabilities
Liabilities
balance at 2022-06-30$146M
10-Q 2022-08-09
$149M
10-K 2024-03-14
+2.4%first · latest
Total liabilities
Liabilities
balance at 2022-09-30$148M
10-Q 2022-11-02
$151M
10-K 2024-03-14
+2.4%first · latest
Net income
NetIncomeLoss
fiscal year 2022-12-31-$333M
10-K 2023-02-28
-$340M
10-K 2024-03-14
-2.3%first · latest · 3 filings carry it
Total liabilities
Liabilities
balance at 2022-12-31$151M
10-K 2023-02-28
$155M
10-K 2024-03-14
+2.3%first · latest · 6 filings carry it

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

Not available for ALLO yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.